Long-term maintenance bacille Calmette-Guérin therapy in high-grade superficial bladder cancer

Urology

Volumn 59, Issue 3, 2002, Pages 414-418

  Iori, F ^a,b   Di Seri, M ^a   De Nunzio, C ^a   Leonardo, C ^a   Franco, G ^a   Spalletta, B ^a   Laurenti, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; BCG VACCINE; CARCINOMA IN SITU; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REMISSION INDUCTION; URINARY BLADDER NEOPLASMS;

EID: 0036191110     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01539-4     Document Type: Article

References (23)

1. Cancer statistics, 2000
2. Stage T1 grade 3 transitional cell carcinoma of the bladder; an unfavorable tumor?
3. Intravesical therapy for transitional cell carcinoma of the bladder; the community practice
4. Intracavitary bacillus Calmette Guérin in the treatment of superficial bladder tumors
5. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder
6. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin
7. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy
8. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors
9. Prognostic factors; back to the future
10. Bacillus Calmette Guérin versus doxorubicin versus thiotepa; a randomized prospective study in 202 patients with superficial bladder cancer
11. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder
12. Five years follow-up of a randomized prospective study comparing intravesical mitomycin C and bacillus Calmette Guérin in patients with superficial bladder carcinoma
13. BCG's mechanism of action-increasing our understanding
14. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors; a prospective, randomized trial
15. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer
16. Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors
17. Long term results and complications of intracavitary bacillus Calmette-Guérin therapy for bladder cancer
18. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder; a randomized Southwest Oncology Group study
19. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder
20. Intravesical BCG instillations in patients with carcinoma in situ and pT1G3 transitional cell carcinoma of the bladder
21. Conservative for stage T1b, grade 3 transitional cell carcinoma of the bladder
22. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder; long term results
23. The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer